Medical Devices; Anesthesiology Devices; Classification of the Spinal Imaging System for Neuraxial Procedures
Key claim: The FDA is placing spinal imaging systems used in neuraxial procedures into the moderate-risk (class II) device category with special controls, which should make it easier for similar products to reach patients while still requiring safety safeguards.
Abstract
(Rule · Health and Human Services Department, Food and Drug Administration) The Food and Drug Administration (FDA) is classifying the spinal imaging system for neuraxial procedures into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the spinal imaging system for neuraxial procedures. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of the safety and effectiveness of the device. We believe this action will also enhance patients’ access to beneficial innovative devices, in part by reducing regulatory burdens.
Why this matters
Each FDA device classification sets the regulatory bar for similar future products: Class II with special controls means new entrants can rely on 510(k) clearance rather than the more burdensome Class III premarket approval process. For patients receiving epidurals, spinals, or other neuraxial procedures, this signals the FDA expects more imaging-assisted guidance tools to reach the market under a defined safety framework.